Industry news

Biocuba is optimistic about a future without barriers

Sergio Held / BioWorld

Now working without the hurdle of a trade embargo, Cuba's largest biopharma group is forging ahead with renewed optimism about the future. uring the recent BIO Latin America conference, a representative from Biocuba Farma, of Havana, said that positive outlook was built since the administration of U.S. President Barack Obama lifted a long-standing embargo against the Caribbean island.

08 November 2016

Clearside Biomedical, Inc. Names Rick McElheny as Vice President, Business Development

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that  Rick McElheny  has been named Vice President, Business Development.

Attorneys counsel at-ready stance on cyber-attacks

Michael Fitzhugh / BioWorld

The rising tide of digital attacks touching politics, finance and retail also poses significant threats for the pharmaceutical and medical device industries. During a Thursday webinar, attorneys at King & Spalding LLP counseled that internal identification of "crown jewel" trade secrets, rigorous protection plans and an at-ready stance for incident response to thefts should form the core of corporate game plans.

Synthetic virus may drive personalized medicine into precision medicine

Judy Mottl / Fierce Biotech

A collaborative effort involving Auburn University, Gen9 and Autodesk has developed a synthetic viral genome for bone cancer research and one which may prove revolutionary in the battle against cancer overall.

New report highlights need to speed patent examination

Mark Grayson / PhRMA

The Center for the Protection of Intellectual Property released a new report, “The Long Wait for Innovation: The Global Patent Pendency Problem,” documenting the growing global challenge of patent pendency – the length of time a patent application is left pending while under review. 

07 November 2016

Miramar Labs, Inc.® Receives U.S. FDA 510(k) Clearance for Reduction of Odor

Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market for reduction of odor when patients are treated with the miraDry system. miraDry is now the first and only FDA cleared device for the non-invasive treatment of odor..

Study suggests orphan drug legislation might be too successful

Nuala Moran / BioWorld

A study by U.K. academics shows that orphan drug legislation designed to incentivize investment in treatments for rare diseases is generating products so profitable that investment in broader indications is being stifled.

Slow start for this year's Latin American meeting in post-upheaval Brazil

Sergio Held / BioWorld

A lackluster start for what is one of the largest annual biotech conferences in Latin America underscored the challenges to the industry in Brazil, a country struggling to recover from a series of political and economic reversals that have thrown the once promising economy into chaos.

03 November 2016

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric disorders, today provided a business update and announced its financial results for the third quarter ended September 30, 2016.

Q3 clearout: Shire dumps rare disease med, Gilead cuts simtuzumab

Ben Adams / Fierce Biotech

It’s that time of year when biopharmas sneak out negative R&D news amid a swath of financial data, and the FierceBiotech team has delved deep into the reports and found out which programs have been quietly dumped.